Aug 28, 2023
Former Schrödinger exec launches RA Capital-backed Superluminal Medicines with $33M. Superluminal Medicines is the latest startup to emerge from the storied Schrödinger execs. With a fresh $33M in funding from RA Capital, the company is setting its sights on reinventing how we treat disease. Their goal? To develop therapies that work beyond the constraints of the traditional medical model. Their approach? To identify and target the root causes of illness, rather than just treating symptoms. Sounds like they're on to something. We'll have to wait and see if they can deliver on their promise. In the meantime, keep your eyes on Superluminal Medicines. They're bound to make waves in the coming years.
